NCT01427257View on ClinicalTrials.gov

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Single Dose PB1023

Single Dose PB1023 Formulation A

DRUG

Single Dose PB1023

Single Dose PB1023 Formulation B

DRUG

Single Dose PB1023

Single Dose PB1023 Formulation B

Trial Locations (1)

55114

Prism Research, Saint Paul

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY